BioSpace News Archive

CytoDyn Inc. announced today additional preliminary results to date from the 20 patients who have completed the open-label portion of the Phase 2 trial for NASH (Nonalcoholic steatohepatitis).

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET.

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,191,953 to the Company, relating to the treatment of stroke symptoms.

GlaxoSmithKline (GSK) plc today announced new data from the DREAMM-9 (DRiving Excellence in Approaches to Multiple Myeloma) phase I trial and two GSK collaborative studies investigating the potential use of Blenrep (belantamab mafodotin-blmf), a first-in-class anti-BCMA (B-cell maturation antigen) therapy, in combination with standard of care therapies in earlier lines of multiple myeloma treatment.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).

Annexon, Inc. (Nasdaq: ANNX), announced safety and dose-response data from its Phase 1 clinical trial of ANX009, the company’s subcutaneously administered product candidate that is designed to block the activity of C1q and the entire classical complement pathway.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a Phase 1 study of GBT021601 (GBT601).

Less than two months after the first breakthrough surgery, NYU Langone Health has performed its second successful investigational xenotransplantation procedure using a genetically engineered pig kidney.

Nektar Therapeutics (NASDAQ:NKTR) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with relapsed/refractory hematologic malignancies at the 63rd American Society of Hematology (ASH) Annual Meeting.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofrontera Bioscience GmbH to evaluate the safety and efficacy of Ameluz® in combination with the red-light lamp BF-RhodoLED® for the treatment of moderate-to-severe acne with photodynamic therapy (Ameluz®-PDT).